Incyte knocking on the door of a new upward trend after today’s 6% pop
Reports of results from the December 1-4 meeting of the American Society of Hematology continue to move biotech stocks. Today it was Incyte's (INCY) turn. The company announced positive results for a Phase 2 trial evaluating Incyte's Jakafi in combination with...
Incyte news continues to rebuild credibility of pipeline
Shares of Incyte  (INCY) climbed 2.51% today on the announcement of positive results from a Phase 2 clinical trial, GEOMETRY mono-1, evaluating MET inhibitor capmatinib in 94 adult patients with advanced non-small cell lung cancer. The company presented the data at...
Incyte beats on revenue, misses on earnings; reports good progress in pipeline
I am on vacation until August 26. I am using that downtime to catch up on some of the earnings reports I missed during the very busy second quarter earnings season. On July 30 Incyte (INCY) reported second quarter earnings of 26 cents a share, 4 cents below the Wall...
FDA delivers less than half a loaf to INCY and LLY in approving Olumiant
Today the U.S. Food & Drug Administration did finally approve Baricitinib, now known as Olumiant, for the treatment of moderately-to-severely active rheumatoid arthritis. But the approval carries more restrictions than expected. The FDA approved only the 2...
Here’s what’s behind the plunge in biotech–and in Incyte and Nektar
I’m sure you’ve noticed. As bad as the losses in the general market have been on some recent days–such as yesterday–the punishment meted out to biotech stocks has been worse.Part of that has been the “usual” pattern in a market that is busy selling “risk.” Biotech stocks always get hit hard in such a period. But there’s more, much more going on that’s specific to the sector. And in fact specific to Merck (MRK) and Incyte (INCY), a biotech that’s in my Jubak Picks Portfolio and where I also hold options in my Volatility Portfolio. The key event here for the sector is the April 5 news that Merck and Incyte were pulling the plug on a clinical trial
FDA sets next date for Incyte arthritis drug, baricitinib
The Food and Drug Administration today announced that its Arthritis Advisory Committee will meet on April 23 to discuss the application by Incyte (INCY) and Eli Lilly (LLY) for approval of baricitinib for the treatment of adult patients with moderately to severely active rheumatoid arthritis
Leveraging near-term Incyte catalysts by adding call options to Volatility Portfolio
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...
Holding Incyte in my Jubak Picks portfolio for mid-year catalysts
When I sold Acadia Pharmaceuticals (ACAD) out of my Jubak Picks portfolio on March 5, one reason I gave was that the catalysts for this biotech were too far out--results from critical drug trials weren't likely to be reported for two years. The reason to hold onto...
Saturday Night Quarterback says, For the next week expect…
A very heavy week for earnings will reach a crescendo on Thursday, November 2 with reports from Alibaba and Apple. The excitement isn’t surprising after the huge earnings that Amazon (AMZN), Alphabet (GOOG), Microsoft (MSFT), and Intel (INTC) delivered this past Thursday, October 26. This week Facebook (FB) is the Wednesday, November 1, Â warmup act.
Some signs the bottom is in for Incyte
This qualifies as a horrendous six months for any stock: Shares of Incyte (INCY) are down from $152.66 on March 15 to $115.19 at the close today, October 2. The shares have been even lower, which is one thing giving me some hope that the pain is coming to an end. The...
Lessons from my bad trade in INCY call options in my Volatility Portfolio
Wow. That sure didn’t work the way I intended. Back on May 23 I added the July 21 $140 calls on Incyte (INCY) to my Volatility Portfolio. Those calls traded at $7.10 that day. As I wrote in my post that day, to make money on these options, I’d need to get a move of $4 or so to move the share price above $140 and to move the options into the money. My logic at the time was pretty simple.
Download Jim’s eBook for Free
